In this context, vascular endothelial growth factor (VEGF)/VEGFR pathway inhibitors such as bevacizumab [180,181,182] and poly(ADP-ribose) polymerase (PARP) inhibitors (like olaparib, niraparib, and rucaparib) are approved by the US Food and Drug Administration [183,184,185] and increasingly utilized in clinical settings for the treatment of ovarian cancer patients [186]. Here, VEGFA is linked to ovarian carcinoma.